

Change of material and Corrections to the Instruction Manual

The Support Screen used with VacuGene™ XL has been changed to a more porous version with improved performance. The information below gives guidelines for the use of the new screen, based on the existing manual (80-1300-50). In addition, corrections for a number of errors in the manual are given.

Section 4. Operations

page 8.

The protocol below is given as an example. It has been optimised for the transfer of λ DNA digested with Hind III, labelled and separated as follows:

Sample: 0.01-0.1 μ g λ DNA digested with Hind III to give fragments in the size range 125-23130 base pairs, and labelled with 32p by an end-fill reaction using Klenow fragment.

Electrophoresis

Gel: 0.7 % Agarose NA in 1 x TBE, 4 mm thick

Electrophoresis: GNA-100, 2 hours at 80 V

Transfer

Membrane: GeneBind 45 nylon membrane

Vacuum pressure: 50 mbar

Blotting times:

Depurination	7 mins
Denaturation	7 mins
Neutralisation	7 mins
Transfer	30 mins

Transfer efficiency: > 95 % for fragments in the size range 2027-23130 bp, according to evaluation of autoradiograms by UltroScan XL and GelScan XL.

Transfer parameters must be optimised for specific applications depending on the sample, gel type etc. (see section 4.5 of the manual).



page 9.

WARNING: When using hazardous chemicals, take all suitable protective measures, such as wearing protective glasses and gloves resistant to the chemicals used. Follow local regulations and instructions for safe operation and maintenance of the system.

The instructions for making up neutralising solutions are as follows:

1.0 M Tris	121.1 g Tris
1.5 M NaCl	87.6 g NaCl
pH 7.5	

Add to 800 ml distilled water and mix to dissolve. Adjust to pH 7.5 with HCL. Make up to a final volume of 1 litre with distilled water. Filter before use through a 0.45 µm filter.

page 11. Replace "see Section 5. A" by "see Section 4.1"

Section 6. Trouble-shooting guide

page 16. Replace "see Section 6. Maintenance" with "see Section 5 Care and Maintenance".
Replace "see Section 5A" with "see Section 4.4"
Replace "see Section 5C" with "see Section 4.3"
Replace "see Section 5D" with "see Section 4.4"

Section 11. VacuGene XL Protocol No. 1

The protocol below is given as an example. It has been optimised for the transfer of Guide Line Φ X-174 Ladder (in the size range 5.4 – 134.7 kb) separated by pulsed-field gel electrophoresis as follows:

Electrophoresis

Gel:	1.2 % Agarose NA in 0.5 x TBE, 4 mm thick
Sample:	0.3 μ g Guide Line Φ X-174 Ladder labelled with 32p by an end-fill reaction using Klenow fragment.
Electrophoresis:	Gene Navigator™, separation parameters according to Application Note "Preparation and Separation of <i>Borrelia burgdorferi</i> plasmid DNA", product no. 18-1030-06

Transfer

Membrane:	GeneBind 45 nylon membrane
Vacuum pressure:	50 mbar
Blotting times:	Depurination 20 mins
	Denaturation 20 mins
	Neutralisation 20 mins
	Transfer 60 mins

Transfer efficiency:	Average of 80 % for fragments in the size range 5-70 kb, according to evaluation of autoradiograms by UltroScan XL and GelScan XL. The transfer of larger fragments could not be measured due to poor labelling efficiency.
----------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The transfer achieved is sufficient for most applications but can be improved by increasing depurination and transfer times. Transfer parameters can be optimised for specific applications depending on the sample, gel type etc. (see Section 4.5 in the manual).

Sections 12, 13 and 14: Protocols Nos. 2,3 and 4.

The times are given as a guide only and should be optimised for the particular application in question (see Section 4.5 in the manual).

www.gehealthcare.com

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden

Gene Navigator and VacuGene are trademarks of GE Healthcare companies. GE, imagination at work and GE monogram are trademarks of General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them. GE Healthcare reserves the right, subject to any regulatory and contractual approval, if required, to make changes in specifications and features shown herein, or discontinue the product described at any time without notice or obligation. Contact your local GE Healthcare representative for the most current information.

© 2006 General Electric Company – All rights reserved.

GE Healthcare Bio-Sciences AB, a General Electric Company.

GE Healthcare Europe GmbH
Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare UK Ltd
Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Bio-Sciences Corp
800 Centennial Avenue, P.O. Box 1327, Piscataway, NJ 08855-1327, USA

GE Healthcare Bio-Sciences KK
Sanken Bldg. 3-25-1, Hyakunincho, Shinjuku-ku, Tokyo 169-0073, Japan



imagination at work